Association between fasting plasma glucose and high-sensitivity C-reactive protein: gender differences in a Japanese community-dwelling population by Kawamoto, Ryuichi et al.
ORIGINAL INVESTIGATION Open Access
Association between fasting plasma glucose
and high-sensitivity C-reactive protein: gender
differences in a Japanese community-dwelling
population
Ryuichi Kawamoto
1,3*, Yasuharu Tabara
2, Katsuhiko Kohara
2, Tetsuro Miki
2, Tomo Kusunoki
1,3, Shuzo Takayama
1,
Masanori Abe
1, Tateaki Katoh
3 and Nobuyuki Ohtsuka
3
Abstract
Background: High sensitivity C-reactive protein (hsCRP) is an acute phase reactant and a sensitive marker of
inflammation. Hyperglycemia can potentially promote the production of CRP. The aim of this study was to
determine whether increased fasting plasma glucose (FPG) levels are associated with elevated hsCRP
concentrations by gender.
Methods: We recruited 822 men (mean age, 61 ± 14 years) and 1,097 women (63 ± 12 years) during their annual
health examination from a single community. We cross-sectionally examined whether FPG levels are associated
with hsCRP concentrations, and whether this association is independent of gender, body mass index (BMI) and
other components of the metabolic syndrome.
Results: In women only, hsCRP increased significantly and progressively with increasing FPG (r = 0.169, P < 0.001).
The stepwise multiple linear regression analysis using hsCRP as an objective variable, adjusted for confounding
factors as explanatory variables, showed that FPG as well as age, BMI, systolic blood pressure, high-density
lipoprotein cholesterol (HDL-C), uric acid, and high molecular weight adiponectin were significantly associated with
hsCRP in women, but not in men. There was significant gender interaction, and an increase in hsCRP levels that
was greater in women with BMI ≥ 25 kg/m
2 and higher FPG than in men.
Conclusions: These results suggested that hsCRP levels increase continuously across the FPG spectrum starting
from the lowest FPG in both men and women. However, increase in hsCRP levels was greater in women than
men.
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Introduction
C-reactive protein (CRP) is an acute phase reactant and
a sensitive marker of inflammation. Several studies sup-
port the concept that high-sensitivity C-reactive protein
(hsCRP), even when within the clinical normal range, is
an important precursor of the metabolic syndrome
(MetS) and type 2 diabetes [1-3], and it may be an
independent predictor that reflects early stage cardiovas-
cular disease (CVD) [4-6].
A recent review of 20 studies revealed that there was
also a significant exponential association between glucose
and CVD in nondiabetic participants that extended below
the usual “diabetic threshold” [7], and fasting plasma glu-
cose (FPG) is an important predictor of CVD after adjust-
ing for potential confounders. Experimental studies have
shown that hyperglycemia stimulates the release of the
inflammatory cytokines tumor necrosis factor-alpha
(TNF-a) and interleukin-6 (IL-6) from various cells such
as monocytes [8]. Recent data have demonstrated that
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flammatory cytokines (e.g., TNF-a and IL-6) produced by
visceral adiposity [9]. Thus, elevated FPG is associated
with elevated concentrations of hsCRP [10-12].
On the other hand, Nakanishi et al. reported that
hsCRP levels are much higher in Westerners than in
Japanese [13], and in women compared with men [3,14].
In addition, gender differences have been reported to be
consistent across all ethnic subgroups even after multi-
variable adjustment [14]. However, the question of
whether modification by gender has an effect on the
association between FPG and inflammation in Japanese
has not been investigated in detail.
The aim of this study was to determine whether ele-
vated FPG levels are associated with elevated hsCRP
concentrations, and whether this association is indepen-
dent of gender, body mass index (BMI) and other con-
founders of CVD. We examined cross-sectional data
from Japanese community-dwelling participants.
Materials and methods
Subjects
The present study is designed as a part of the Nomura
study [15]. Subjects were selected through a commu-
nity-based annual check-up process in a rural town
located in Ehime prefecture, Japan. Information on med-
ical history, present conditions, and drugs were obtained
by interview. Other characteristics, such as smoking and
alcohol habits, and medication, were investigated by
individual interviews using a structured questionnaire.
The sample population included 822 men and 1,097
women. The Ethics Committee of Ehime University
School of Medicine approved all the procedures and
each subject gave informed consent to participate.
Evaluation of Risk Factors
Information on demographic characteristics and risk fac-
tors was collected using clinical files. Body mass index was
calculated by dividing weight (in kilograms) by the square
of the height (in meters). We measured blood pressure
with an appropriate-sized cuff on the right upper arm of
the subjects in a sedentary position using an automatic
oscillometric blood pressure recorder (BP-103i; Colin,
Aichi, Japan) while they were seated after having rested for
at least 5 min. Smoking status was classified into never
smokers, past smokers, and current smokers. Daily alcohol
consumption was measured using the Japanese liquor unit
in which a unit corresponds to 22.9 g of ethanol, and the
participants were classified into never drinkers, occasional
drinkers (<1 unit/day), and daily drinkers (≥1u n i t / d a y ) .
Total cholesterol (T-C), triglycerides (TG), high-density
lipoprotein cholesterol (HDL-C), FPG, creatinine (enzy-
matic method), uric acid, immuno-reactive insulin (IRI),
high molecular weight (HMW) adiponectin (Fujirebio,
Tokyo, Japan), and hsCRP concentration (Dade Behring
Inc., Marburg, Germany) were measured during fasting.
Plasma hsCRP concentration was measured using a Behr-
ing BN II nephelometer (Dade Behring Inc., Marburg,
Germany) and the inter- and intra-assay coefficient varia-
tions were 3.2 and 6.7%, respectively. Low-density lipopro-
tein cholesterol (LDL-C) level was calculated by the
Friedewald formula. Participants with TG levels ≥400 mg/
dL were excluded.
Statistical Analysis
Statistical analysis was performed using PASW Statistics
17.0 (Statistical Package for Social Science Japan, Inc.,
Tokyo, Japan). Data are presented as the mean ± standard
deviation (SD) unless otherwise specified, and in cases of
parameters with non-normal distributions (TG, FPG, IRI,
HMW adiponectin, and hsCRP) the data are shown as
median (interquartile range) values. In all analyses, para-
meters with non-normal distributions were used after log-
transformation. Differences among five groups divided
according to categories of FPG status and Type 2 diabetes
were analyzed by ANOVA or chi-square (X
2)t e s t .S t e p -
wise multiple linear regression analysis was used to evalu-
ate the contribution of each confounding factor for
hsCRP. The synergistic effect of gender and the confound-
ing factors was evaluated using a general linear model.
ANCOVA was performed using a general linear model
approach to determine the association between confound-
ing factors and hsCRP. In these analyses, hsCRP was the
dependent variable, the five categories of FPG status were
the fixed factors, and confounding factors were added as
covariates. A p-value < 0.05 was considered significant.
Results
Subject background characteristics
The characteristics of the study participants in relation to
gender and FPG category are illustrated in Table 1 and
Table 2. The study included 822 men, aged 61 ± 14
(range, 20-89) years, and 1,097 women, aged 63 ± 12
(range, 21-88) years. Subjects with type 2 diabetes were
the oldest among the men. For both men and women,
BMI, systolic blood pressure (SBP), diastolic blood pres-
sure (DBP), prevalence of antihypertensive medication,
TG, FPG, IRI, and hsCRP were higher in those with the
highest category of normal FPG, IFG, and type 2 diabetes
than in those with the lowest and middle categories of
normal FPG. History of CVD, HDL-C, and antilipidemic
medication in men, and smoking status and HDL-C in
women did not differ significantly among the five groups
Relationship between hsCRP and various characteristics
according to gender
As shown in Table 3, hsCRP increased significantly in
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both genders, but with a decrease in HDL-C and HMW
adiponectin. In addition, hsCRP was also positively cor-
related with SBP, DBP, TG, LDL-C, antilipidemic medi-
cation, FPG, and hypoglycemic medication in women
only. IRI was stronger correlated with hsCRP than FPG
in both genders.
The stepwise multiple linear regression analysis using
hsCRP as an objective variable, adjusted for confounding
f a c t o r sa se x p l a n a t o r yv a r i a b l e si ss h o w ni nT a b l e3 .I n
men, age, BMI, smoking status, TG, HDL-C, uric acid,
and IRI were significantly associated with hsCRP, and in
women, age, BMI, SBP, HDL-C, uric acid, FPG, and
HMW adiponectin were significantly associated with
hsCRP.
General linear model for interactions between gender
and confounding factors
To further investigate whether the interaction between
gender and FPG, and the confounding factors could
influence hsCRP, a general linear model for hsCRP was
analyzed using the parameters in Table 3 and gender
including interaction between gender and smoking sta-
tus, SBP, TG, IRI, FPG, and HWM adiponectin (Table
4). The results revealed that the interaction between
gender and FPG (F =5 . 5 4 7 ,P = 0.019) was significantly
associated with hsCRP, in addition to gender, age, BMI,
SBP, HDL-C, uric acid, FPG, and HMW adiponectin.
This finding indicates that the association between FGB
and hsCRP was significantly different between men and
women.
Relationship between FPG and hsCRP according to
gender
In women only, hsCRP increased significantly and pro-
gressively with increasing FPG (r = 0.169, P < 0.001)
(Figure 1).
Geometric mean levels of hsCRP and standard error bar
according to gender, obesity, and FPG category
Figure 2 shows the geometric mean levels of CRP
(adjusted for age, smoking status, SBP, HDL-C, uric
acid, and HMW adiponectin) according to gender, obe-
sity, and FPG category. Adjusted geometric mean levels
of hsCRP in obese (BMI ≥25 kg/m
2) men with the low-
est, second lowest, and highest values of normal FPG,
IFG, and type 2 diabetes were 0.716, 0.867, 0.917, 0.947,
and 1.014, respectively. The respective adjusted geo-
metric mean levels of hsCRP for obese women were
0.796, 0.868, 0.801, 0.954, and 1.108, respectively (Pf o r
trend = 0.002). As shown, there was a significant gender
interaction, and the increase in hsCRP levels was greater
Table 1 Clinical characteristics of male participants according to fasting plasma glucose category
Men, N = 822 Normal fasting plasma glucose IFG Type-2 diabetes
or >125 mg/dL
P-value*
Characteristics FBS <90
N = 200
90-99
N = 286
100-109
N = 143
110-125
N=6 3
N = 130
Age (years) 57 ± 15 60 ± 14 63 ± 13 60 ± 12 66 ± 9 <0.001
Body mass index (kg/m
2) 22.6 ± 2.9 23.6 ± 2.8 24.5 ± 3.1 24.7 ± 3.2 23.8 ± 2.7 <0.001
Smoking status, % 29.0/19.5/51.5 46.9/22.7/30.4 43.4/29.4/27.3 44.4/28.6/27.0 46.2/30.8/23.1 <0.001
Alcohol consumption, % 15.0/33.0/52.0 12.9/31.8/55.2 17.5/20.3/62.2 3.2/22.2/74.6 20.0/26.2/53.8 0.005
History of CVD, % 7.0 9.1 10.5 9.5 15.4 0.160
Systolic blood pressure (mmHg) 130 ± 17 140 ± 20 147 ± 18 147 ± 19 147 ± 20 <0.001
Diastolic blood pressure (mmHg) 80 ± 10 84 ± 11 87 ± 11 90 ± 12 87 ± 10 <0.001
Antihypertensive medication, % 13.5 22.4 32.9 33.3 33.8 <0.001
Triglycerides (mg/dL) 91 (66-133) 94 (73-126) 104 (75-142) 105 (77-165) 96 (71-162) 0.014
HDL cholesterol (mg/dL) 59 ± 14 59 ± 14 60 ± 16 59 ± 16 58 ± 16 0.880
LDL cholesterol (mg/dL) 105 ± 31 111 ± 29 118 ± 34 107 ± 33 111 ± 33 0.003
Antilipidemic medication, % 2.5 3.5 4.9 1.6 6.9 0.229
Serum uric acid (mg/dL) 5.9 ± 1.2 6.0 ± 1.4 6.1 ± 1.4 6.2 ± 1.4 5.5 ± 1.4 <0.001
Fasting plasma glucose (mg/dL) 86 (83-88) 94 (92-96) 103 (101-105) 115 (112-118) 122 (100–150) <0.001
Immuno-reactive insulin (μU/mL) 3.65 (2.00-5.48) 4.60 (3.20-6.90) 6.20 (3.50-8.30) 6.60 (4.70-8.70) 4.80 (3.30-8.20) <0.001
Hypoglycemic medication, % 0 0 0 0 25.4 <0.001
HMW adiponectin (μg/mL) 3.65 (2.37-6.09) 3.41 (1.97-5.52) 3.66 (1.91-5.10) 2.67 (1.70-4.99) 3.03 (1.86-4.88) 0.030
hsCRP (mg/dL) 0.046 (0.026-0.096) 0.046 (0.025-0.104) 0.057 (0.028-0.112) 0.069 (0.042-0.150) 0.060 (0.035-0.117) 0.033
CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HMW. High molecular weight; hsCRP, high sensitivity C-reactive protein.
Data presented are mean ± standard deviation. Data for triglycerides, fasting plasma glucose, HMW adiponectin, Immuno-reactive insulin, and hsCRP were
skewed, and are presented as median (interquartile range) and were log-transformed for analysis. *P-value: ANOVA or X
2 -test.
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Women, N = 1,097
mg/dL
Normal fasting plasma glucose IFG Type-2 diabetes
or >125 mg/dL
P -value*
Characteristics FBS <90
N = 409
90-99
N = 391
100-109
N = 152
110-125
N=5 2
N=9 3
Age (years) 58 ± 13 64 ± 10 67 ± 9 68 ± 9 66 ± 10 <0.001
Body mass index (kg/m
2) 22.5 ± 3.1 23.4 ± 3.2 24.4 ± 3.4 24.9 ± 3.8 24.6 ± 3.9 <0.001
Smoking status, % 97.1/0.7/2.2 98.5/0.5/1.0 95.4/2.0/2.6 98.1/1.9/0 98.9/0/1.1 0.409
Alcohol consumption, % 58.4/35.7/5.9 66.8/26.6/6.6 69.1/27.0/3.9 69.6/28.8/1.9 73.1/24.7/2.2 0.035
History of CVD, % 5.4 5.6 12.5 5.8 9.7 0.025
Systolic blood pressure (mmHg) 131 ± 22 141 ± 22 145 ± 24 151 ± 22 144 ± 23 <0.001
Diastolic blood pressure (mmHg) 77 ± 12 82 ± 11 83 ± 12 86 ± 11 81 ± 11 <0.001
Antihypertensive medication, % 15.6 23.5 38.2 50.0 44.1 <0.001
Triglycerides (mg/dL) 84 (61-114) 92 (69-128) 90 (70-135) 106 (78-144) 94 (70-155) <0.001
HDL cholesterol (mg/dL) 66 ± 15 65 ± 15 65 ± 16 65 ± 15 61 ± 16 0.127
LDL cholesterol (mg/dL) 120 ± 29 127 ± 29 134 ± 30 131 ± 28 132 ± 31 <0.001
Antilipidemic medication, % 3.7 6.1 9.2 17.3 11.8 <0.001
Serum uric acid (mg/dL) 4.3 ± 1.0 4.5 ± 1.0 4.6 ± 1.1 4.8 ± 0.9 4.6 ± 1.1 <0.001
Fasting plasma glucose (mg/dL) 86 (82-88) 94 (92-97) 103 (101-105) 116 (113-120) 126 (103-150) <0.001
Immuno-reactive insulin (μU/mL) 4.80 (3.40-6.80) 6.20 (4.50-8.60) 7.40 (5.25-11.5) 9.50 (6.75-12.9) 7.80 (5.20-11.2) <0.001
Hypoglycemic medication, % 0 0 0 0 37.6 <0.001
HMW adiponectin (μg/mL) 7.15 (4.72-10.3) 6.82 (4.65-10.1) 5.94 (4.12-8.83) 4.82 (3.58-7.73) 5.22 (3.20-8.18) <0.001
hsCRP (mg/dL) 0.035 (0.017-0.061) 0.043 (0.024-0.089) 0.048 (0.028-0.093) 0.063 (0.031-0.124) 0.080 (0.034-0.198) <0.001
CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HMW. High molecular weight; hsCRP, high sensitivity C-reactive protein.
Data presented are mean ± standard deviation. Data for triglycerides, fasting plasma glucose, immuno-reactive insulin, and HMW adiponectin, and hsCRP were
skewed, and are presented as median (interquartile range) and were log-transformed for analysis. *P-value: ANOVA or X
2-test.
Table 3 Relationship between hsCRP and various characteristics according to gender
Men, N = 822 Women, N = 1,097
Characteristics r (P-value) b (P-value) r (P-value) b (P-value)
Age (years) 0.096 (0.006) 0.165 (<0.001) 0.202 (<0.001) 0.211 (<0.001)
Body mass index (kg/m
2) 0.188 (<0.001) 0.129 (0.002) 0.355 (<0.001) 0.245 (<0.001)
Smoking status, % 0.040 (0.249) 0.102 (0.005) 0.005 (0.863) ——————
Alcohol consumption, % -0.017 (0.637) —————— -0.080 (0.008) ——————
History of CVD, % 0.086 (0.013) —————— 0.073 (0.016) ——————
Systolic blood pressure (mmHg) 0.049 (0.164) —————— 0.126 (<0.001) -0.081 (0.009)
Diastolic blood pressure (mmHg) 0.028 (0.426) —————— 0.103 (0.001) ——————
Antihypertensive medication, % 0.115 (0.001) —————— 0.138 (<0.001) ——————
Triglycerides (mg/dL) 0.040 (0.257) -0.099 (0.012) 0.209 (<0.001) ——————
HDL cholesterol (mg/dL) -0.190 (<0.001) -0.152 (<0.001) -0.196 (<0.001) -0.061 (0.040)
LDL cholesterol (mg/dL) 0.028 (0.420) —————— 0.179 (<0.001) ——————
Antilipidemic medication, % 0.036 (0.301) —————— 0.079 (0.009) ——————
Serum uric acid (mg/dL) 0.126 (<0.001) 0.117 (0.001) 0.285 (<0.001) 0.164 (<0.001)
Fasting plasma glucose (mg/dL) 0.067 (0.056) —————— 0.232 (<0.001) 0.121 (<0.001)
Immuno-reactive insulin (μU/mL) 0.162 (<0.001) 0.087 (0.040) 0.263 (<0.001) ——————
Hypoglycemic medication, % 0.027 (0.445) —————— 0.082 (0.007) ——————
HMW adiponectin (μg/mL) -0.094 (0.007) —————— -0.197 (<0.001) -0.107 (0.001)
R
2 —————— 0.090 (<0.001) —————— 0.227 (<0.001)
hsCRP, high sensitivity C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HMW. High molecular weight. Data presented are mean ±
standard deviation. Data for triglycerides, fasting plasma glucose, immuno-reactive insulin, and hsCRP were skewed and log-transformed for analysis. *r, Pearson’s
correlation coefficient; b, standard regression coefficient.
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Level.
Discussion
In this cross-sectional, population-based study, we deter-
mined the relation between glucose levels and hsCRP by
gender in healthy participants. This study showed that
hsCRP levels increase continuously across the spectrum
of FPG, starting from the lowest FPG in both men and
women. When analyzing FPG and BMI simultaneously,
it is apparent that increased hsCRP levels are mainly
due to increased hsCRP concentrations according to the
status of obesity. These findings suggest that the FPG-
hsCRP relationship is stronger for subjects with obesity
than for those without. In addition, increase in hsCRP
levels was greater in women than men, and we demon-
strated that there is a gender interaction between
increased FPG and hsCRP after adjustment for age,
BMI, smoking status, SBP, HDL-C, uric acid, FPG, and
HMW adiponectin. To our knowledge, few studies indi-
cate modification of the effect by gender in the associa-
tion between FPG and inflammation in Japanese
community-dwelling adults.
Several previous studies show that gender, FPG and
obesity are independent confounding factors for
increased hsCRP. In a total of 1,737 Korean subjects
aged >60 years, multiple regression analysis using
hsCRP as a dependent variable showed that BMI and
white blood cell count as well as fasting insulin, post-
load 2 h glucose, hematocrit and LDL-C were significant
independent variables [16]. In 520 Chinese patients with
type 2 diabetes, insulin resistance was associated with
CRP levels independent of abdominal obesity [17]. Unek
et al. [18] report that obese patients show a significant
increase in hsCRP and soluble CD40 ligand levels com-
pared with normal weight subjects, which might contri-
bute to the known proinflammatory milieu found in
these patients. In a total of 16,616 men and non-preg-
nant women aged ≥ 17 years, after adjustment for
potential confounders, the adjusted OR of obese men
and women for increased CRP was 2.13 (95% CI, 1.56-
2.91) and 6.21 (95% CI, 4.94-7.81), respectively. In addi-
tion, BMI was associated with increased CRP levels in
women only [19]. In a population-based cross-sectional
study, fasting glucose remained significantly and inde-
pendently related to CRP levels [10,11], and hsCRP as
well as the insulin resistance indices increased gradually
even in the normal fasting glucose range, supporting the
rationale for expanding the range of fasting hyperglyce-
mia [12]. Moreover, an increase in CRP levels was
greater in women than men in the obesity and higher
fasting glucose category, and this association was more
pronounced in women [11]. In our study, increased FPG
levels were positively associated with increased hsCRP,
independent of other confounders, especially in obese
women and the association was also shown to be within
the normal range in obese participants.
There are several possible mechanisms linking FPG,
gender, obesity and hsCRP. This result shows that high
FPG levels can increase levels of key proteins (e.g.,
hsCRP) that result in inflammation. In experimental stu-
dies, human monocytes show a glucose-dependent
increase in TNF-a and IL-6 production [20-22]. In
female Turkish subjects, subjects with impaired glucose
tolerance had higher fasting serum TNF-a levels than
subjects with normal glucose tolerance (p < 0.01), and
serum TNF-a and IL-6 concentrations were elevated
during the glucose challenge (for each comparison, p <
0.01) [23]. It has also been demonstrated that IL-6 and
high glucose synergistically stimulate matrix metallopro-
teinase-1 (MMP-1) expression in mononuclear phago-
cytes, and IL-6 and high glucose synergistically
upregulate MMP-1 expression by U937 mononuclear
phagocytes [24]. Obesity per se is also an important risk
factor of the development of type 2 diabetes and is asso-
ciated with low-grade systemic inflammation [25].
Furthermore, Fat accumulation in the liver or adipose
tissues can induce inflammatory cytokines such as TNF-
a, IL-6, and IL-8 [26]. These cytokines produced by adi-
pocytes stimulate hepatic synthesis of CRP, which is an
acute-phase protein, and influence insulin resistance as
Table 4 Gender interaction between hsCRP and various
subject characteristics
N = 1,919
Characteristics F (P-value)
Gender (men = 0, Women = 1) 4.573 (0.033)
Age (years) 68.24 (<0.001)
Body mass index (kg/m
2) 59.82 (<0.001)
Smoking status 1.925 (0.165)
Systolic blood pressure (mmHg) 4.839 (0.028)
Triglycerides (mg/dL) 1.452 (0.228)
HDL cholesterol (mg/dL) 12.82 (<0.001)
Serum uric acid (mg/dL) 38.38 (<0.001)
Fasting plasma glucose (mg/dL) 13.30 (<0.001)
Immuno-reactive insulin (μU/mL) 1.491 (0.222)
HMW adiponectin (μg/mL) 10.27 (0.001)
Gender *Smoking status 0.751 (0.386)
Gender *Systolic blood pressure 0.050 (0.823)
Gender *Triglycerides 0.845 (0.358)
Gender *Immuno-reactive insulin 0.056 (0.814)
Gender *Fasting plasma glucose 5.547 (0.019)
Gender *HMW adiponectin 1.709 (0.191)
hsCRP, high sensitivity C-reactive protein; HMW, high molecular weight. Data
for hsCRP, triglycerides, fasting plasma glucose, immuno-reactive insulin, and
HMW adiponectin were skewed and log-transformed for analysis.
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these factors result in the production of CRP.
Other mechanisms may contribute to the altered glu-
cose metabolism demonstrated. Adiponectin is an adipo-
cyte-secreted cytokine, which has insulin sensitizing,
anti-inflammatory, and anti-atherosclerotic properties
[30,31], and is decreased in persons that are obese and
have diabetes [32]. Decreased adiponectin could affect
blood glucose and systemic inflammation. However, in
our study, an association between FPG and hsCRP
remained significant after adjusting for confounding fac-
tors including BMI and HMW adiponectin.
Our finding showed that gender interaction in the asso-
ciation between MetS and hsCRP suggest that hormones
may play an important role in the inflammatory mechan-
ism [33,34]. In our study, increased BMI was associated
with increased hsCRP concentrations in both genders,
however, the correlation coefficients between hsCRP and
BMI were much higher in women (r = 0.355) than in
men (r = 0.188). These results demonstrated that
i n f l a m m a t o r yr e s p o n s em a yb em o r ee n h a n c e dt h r o u g h
adipose tissue-secreted cytokine expression in women
[11]. Thus, sex hormones may be responsible for the
association of fasting glucose with hsCRP. In postmeno-
pausal women, this gender-specific effect of fasting glu-
cose on inflammation might help to explain an increase
in the relative risk for MetS and CVD [35]
Several limitations should be considered in this study.
First, our cross-sectional study design does not eliminate
potential causal relationships between CRP and FPG. Sec-
ond, FPG categories are based on a single assessment of
blood, which may introduce a misclassification bias. Third,
we could not eliminate the possible effect of medication for
hypertension on the present findings. Therefore the demo-
graphics and referral source may limit generalizability.
In conclusion, the present study showed that FPG
levels are strongly associated with hsCRP in the general
population with obesity. The underlying mechanism
behind this relationship is unclear, but seems to be inde-
pendent of traditional cardiovascular risk factors such as
)DVWLQJSODVPDJOXFRVHPJG/
Figure 1 Relationship between fasting plasma glucose (FPG) and high sensitivity C-reactive protein (hsCRP) according to gender.I n
women, hsCRP increased significantly and progressively with increasing FPG (r = 0.169, P < 0.001). Test of significance was based on log-
transformed values for analysis. P -value: Pearson’s correlation coefficient.
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pressure, lipids, or uric acid. Thus, the FPG levels (espe-
cially, higher values of normal FPG, IFG, and women) in
persons with obesity might provide an important marker
for the assessment of atherogenic risk as well as a thera-
peutic target for the modification of atherogenic risks. For
healthy community-dwelling persons, prospective popula-
tion-based studies are needed to investigate the mechan-
isms underlying this association to determine whether
intervention, such as effective lifestyle modifications and
medication (e.g., antihypertensive, antilipidemic, and dia-
betic medication) that decrease BMI and FPG in adults,
will decrease hsCRP.
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Figure 2 Geometric mean levels of high sensitivity C-reactive protein (hsCRP) and standard error bars, according to obesity, and
fasting plasma glucose (FPG) category. Obesity was defined as a body mass index of ≥25 kg/m
2. hsCRP levels were adjusted for age,
smoking status, systolic blood pressure, high-density lipoprotein cholesterol, uric acid, and high molecular weight (HMW) adiponectin. Data for
HMW adiponectin and hsCRP were skewed, and log-transformed for analysis.
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